Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Illumina's Tests for Thrombosis

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina said after the close of the market Tuesday that it has received 510(k) clearance from the US Food and Drug Administration for its VeraCode Genotyping Test for Factor V mutation (Leiden) and Factor II mutation (prothrombin).

The test is comprised of Illumina's VeraCode digital microbead technology, which it acquired through the purchase of CyVera in 2004, as well as proprietary assay chemistry. The VeraCode technology is the basis for Illumina's BeadXpress system, a platform for research and clinical development applications.

The BeadXpress system is FDA-approved for in vitro diagnostic use only with the VeraCode Genotyping Test for Factor V and Factor II. Factor V is the most common genetic defect for inherited thrombosis, and Factor II is the second-most common. Two weeks ago, Illumina receive a separate clearance from FDA for the BeadXpress system.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.